Improving the outcomes of multiple myeloma patients with high-risk abnormalities (HRA) continues to pose a therapeutic challenge, but the future of multiple myeloma treatment is bright, with so many active drugs and immunotherapies on the horizon, a recent Amgen-sponsored educational meeting in Perth heard. Doctor M Hasib Sidiqi from the Fiona Stanley Hospital, Murdoch, WA ...
In pursuit of improved outcomes in high-risk multiple myeloma
Sponsored by Amgen Australia Pty Ltd
29 Oct 2019